HIV prevention breakthrough sparks calls for affordability
"Lenacapavir offers a highly effective, tolerable, and discreet choice that could potentially improve PrEP uptake and persistence, helping us to reduce HIV in cisgender women globally."
PREMIUM Health
UNAIDS executive director Winnie Byanyima (3rd right), Gilead Vice President Jared Baeten, and others. Courtesy photo
By NewVision Reporter
Journalists @NewVision
The international AIDS community erupted in excitement at the International AIDS Conference as groundbreaking results from a pivotal HIV prevention trial were unveiled.
Lenacapavir, a long-acting injectable pre-exposure